Subject: Protect access to Medicaid and the Affordable Care Act!
Dear Senator [insert name here],
On behalf of the cystic fibrosis (CF) community and as a concerned constituent, I write asking you to oppose changes included in the reconciliation bill passed by the House of Representatives (HR 1) that would disrupt the cystic fibrosis community’s access to critical care through Medicaid and Affordable Care Act Marketplace insurance plans.
Cystic fibrosis is a chronic, life-threatening genetic condition that primarily impacts the lungs and digestive system, and affects about 40,000 people in the United States. Cystic fibrosis care involves regular medical visits with a team of specialists, specialized equipment and supplies, supplements, and, most importantly, novel prescription medicines that have drastically improved the health outcomes of 90% of the CF community. This network of care, especially high-cost medication, is only accessible to people living with CF through robust and continuous health insurance coverage.
42% of people and 58% of children younger than 10 living with CF are covered under Medicaid or state programs. Disrupting Medicaid and Affordable Care Act Marketplace plans would jeopardize the cystic fibrosis community’s access to this lifesaving care. The Congressional Budget Office calculated that 10.9 million people may become uninsured over the next 10 years due to these changes, many of whom will be people living with CF. Many analyses attribute this loss of coverage among eligible individuals to administrative burden and incorrect or missing paperwork.
I ask you to oppose the proposed measures in the reconciliation bill that will cause eligible people and families living with CF to lose essential, lifesaving insurance coverage due to administrative obstacles. I also urge you to oppose policies that raise out-of-pocket costs and premiums for patients and their families who already struggle with the costs of living with CF.
These measures include:
I also ask you to ensure that the Affordable Care Act Marketplace plan enhanced premium tax credits do not expire, which would cause out-of-pocket premium costs to increase by an average of 75%.
The proposed changes in the reconciliation bill would destabilize lifesaving access to care for our community. Cystic fibrosis is one of the most successful stories in rare disease, as breakthrough medications have transformed health outcomes for people living with CF over the past decade. Our community has fought hard to get to where we are and we cannot let administrative burdens disrupt or block access to these transformative breakthroughs. We urge you to oppose cuts that jeopardize access to lifesaving care and to ensure that the story of cystic fibrosis continues to be one of the most successful stories in American medical history.
Sincerely,
[Constituent]
Subject: Support the PASTEUR Act to Defend Against Antimicrobial Resistance!
As a concerned constituent and as an advocate of the cystic fibrosis (CF) community, I urge you to support the passage of the PASTEUR Act (H.R. 2940/S. 1355) to combat the growing threat of antimicrobial resistance (AMR). AMR is a rapidly evolving danger to the American public and disproportionately affects people living with CF. People with CF require treatment with antimicrobial medicines from a young age to fight recurring lung infections, so they are at a greater risk of their infections becoming increasingly resistant over time, leading to end-stage disease and complicating transplant eligibility.
The PASTEUR Act is a proposed bipartisan, bicameral legislation that would address the current lack of an effective pipeline for antimicrobials by spurring investment in novel antimicrobial development. This act supports a subscription-style model that ensures that innovators have a sustainable financial incentive and path to profitability, thus removing a significant barrier to antimicrobial development. The PASTEUR Act not only funds the production of new antimicrobials, but also creates diagnostic tools, surveillance systems, vaccines, and other alternative treatments to ensure that new medicines are quickly generated and used safely and effectively.
To protect the lives of people living with CF and all those whose lives are threatened by AMR, I urge you to act now and quickly pass the PASTEUR Act.
Subject: Support the HELP Copays Act to Protect Critical Patient Assistance!
As a concerned constituent and as an advocate of the cystic fibrosis (CF) community, I urge you to support the passage of the The Help Ensure Lower Patient Copays (HELP) Copays Act (S.864) to protect patients from copay adjustment programs, including accumulators and maximizers. Copay accumulator programs used by insurers and pharmacy benefit managers (PBMs) siphon copay assistance away from patients by not counting third-party assistance towards cost-sharing requirements such as deductibles and out-of-pocket (OOP) maximums.
The HELP Copays Act restricts the use of these programs by including any third-party assistance toward patients’ individual and family cost-sharing requirements. The act also closes the loophole that allows insurers and PBMs to deem a product “non-essential,” which avoids annually set OOP maximums.
The HELP Copays Act would protect patients from copay adjustment programs and allow copay assistance to work as intended– to make prescription drugs affordable for patients. Copay assistance is critical for patients who rely on brand-name drugs without generic alternatives. Copay adjustment programs, while designed to prevent overutilization, are not transparent and can levy financial pain against often unknowing victims. They must be removed from the health insurance marketplace through the HELP Copays Act.